Iovance Biotherapeutics (IOVA) Stock Surges 40% After Record Q2 Revenue Beat
TLDR
- IOVA stock surged more than 40% to a new 52-week high after Q2 results beat Wall Street estimates
- Product revenue hit a record $99.3M, up ~66% year-over-year, beating consensus by $11.5M
- Amtagvi generated ~$91M in U.S. revenue, growing 40% from Q4 2025
- Gross margin reached 56%, with management expecting continued improvement ahead
- Iovance is now reviewing its full-year 2026 revenue guidance of $350M-$370M upward
Iovance Biotherapeutics stock jumped more than 40% on Thursday, hitting a new 52-week high after the company posted record Q2 2026 results that topped analyst expectations by a wide margin.
Iovance Biotherapeutics, Inc., IOVA
Product revenue came in at $99.3 million for the quarter, up from $59.9 million in Q2 2025. That beat the Street consensus by $11.5 million.
The growth was driven almost entirely by Amtagvi, its FDA-approved cell therapy for late-stage melanoma. The treatment brought in roughly $91 million in U.S. revenue, a 40% jump from Q4 2025.
Today, Iovance reported Q2 2026 financial results and corporate updates — a quarter of strong momentum across the business. Read the press release: https://t.co/ZZ7jgAPKzg | Join our live webcast at 8:30 a.m. ET today or listen to the replay: https://t.co/HQYDrJFuMM pic.twitter.com/NqnEDAvygv
… Continue reading the full article at the original source below.
